Warning to ophthalmologists

Article

"When treating patients with DME, ophthalmologists should consider the role of the glitazone class of drugs," warn the authors of a study published in the April issue of the American Journal of Ophthalmology.

"When treating patients with DME, ophthalmologists should consider the role of the glitazone class of drugs," warn the authors of a study published in the April issue of the American Journal of Ophthalmology.

Whilst the diabetes drug class, glitazones has been associated with an increased risk of diabetic macular oedema (DME) in the past, this piece of research confirms that the drugs, which include pioglitazone (Actos) and rosiglitazone (Avandia) are 'modestly associated' with increased DME.

Related Videos
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
Dr Mary Elizabeth Hartnett speaks with David Hutton of Ophthalmology Times
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
Related Content
© 2023 MJH Life Sciences

All rights reserved.